Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017039525) METHOD OF TREATING A DOPAMINE RELATED DISORDER IN A SUBJECT BY ADMINISTERING LEVODOPA, IN COMBINATION WITH A DOPAMINE DECARBOXYLASE INHIBITOR AND A CATECHOL-O-METHYLTRANSFERASE INHIBITOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/039525 International Application No.: PCT/SE2016/050828
Publication Date: 09.03.2017 International Filing Date: 05.09.2016
IPC:
G01N 33/94 (2006.01) ,A61K 31/198 (2006.01) ,A61K 31/277 (2006.01) ,A61P 25/16 (2006.01) ,G01N 33/15 (2006.01) ,A61P 25/00 (2006.01) ,G01N 33/487 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
94
involving narcotics
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
185
Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19
Carboxylic acids, e.g. valproic acid
195
having an amino group
197
the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
198
Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
275
Nitriles; Isonitriles
277
having a ring, e.g. verapamil
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
14
for treating abnormal movements, e.g. chorea, dyskinesia
16
Anti-Parkinson drugs
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
15
Medicinal preparations
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
483
Physical analysis of biological material
487
of liquid biological material
Applicants:
LOBSOR PHARMACEUTICALS AKTIEBOLAG [SE/SE]; Kolonivägen 16 741 44 Knivsta, SE
Inventors:
BOLSÖY, Roger; SE
Agent:
BRANN AB; (Drottninggatan 27) P.O. Box 3690 103 59 Stockholm, SE
Priority Data:
62/214,74204.09.2015US
PCT/SE2015/05093904.09.2015SE
Title (EN) METHOD OF TREATING A DOPAMINE RELATED DISORDER IN A SUBJECT BY ADMINISTERING LEVODOPA, IN COMBINATION WITH A DOPAMINE DECARBOXYLASE INHIBITOR AND A CATECHOL-O-METHYLTRANSFERASE INHIBITOR
(FR) PROCÉDÉ DE TRAITEMENT D’UN TROUBLE LIÉ À LA DOPAMINE CHEZ UN SUJET PAR ADMINISTRATION DE LÉVODOPA, EN COMBINAISON AVEC UN INHIBITEUR DE LA DOPAMINE DÉCARBOXYLASE ET UN INHIBITEUR DE CATÉCHOL-O-MÉTHYLTRANSFÉRASE
Abstract:
(EN) The invention relates to a method of treating a dopamine related disorder in a subject, the method comprises the steps of administering therapy to a subject, the therapy comprising a plurality of doses of levodopa over a selected time period, in combination with a dopamine decarboxylase inhibitor (DDI) and a catechol-O-methyltransferase (COMT) inhibitor, wherein: (i) the dose of levodopa is lower; (ii) the dose of DDI is lower; (iii) the dosing of levodopa is less frequent; and/or (iv) the dosing of DDI is less frequent As compared with a reference regimen over the selected time period.
(FR) La présente invention concerne un procédé de traitement d’un trouble lié à la dopamine chez un sujet, le procédé comprenant les étapes d’administration d’une thérapie à un sujet, la thérapie comprenant une pluralité de doses de lévodopa pendant une période sélectionnée, en combinaison avec un inhibiteur de dopamine décarboxylase (DDI) et un inhibiteur de catéchol-O-méthyltransférase (COMT), dans lequel : (i) la dose de lévodopa est plus faible ; (ii) la dose de DDI est plus faible ; (iii) l’administration de lévodopa est moins fréquente ; et/ou (iv) l’administration de DDI est moins fréquente, par rapport à un régime de référence pendant la période sélectionnée.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)